Status:
COMPLETED
An Observational, Prospective, Safety Study of Mircera (Monopegylated Epoetin Beta) in Clinical Practice
Lead Sponsor:
Hoffmann-La Roche
Conditions:
Kidney Disease, Chronic
Eligibility:
All Genders
18+ years
Brief Summary
This national study was a post-marketing surveillance study conducted in Korea from 29 August 2008 to 28 August 2012 to meet local regulatory requirements for Mircera (monopegylated-epoetin beta). Pro...
Eligibility Criteria
Inclusion
- Adult, aged \>18 years
- Participants with stage 3-5 chronic kidney disease and hemodialyzed participants
- Signed informed consent
Exclusion
- Current participation in a clinical study
Key Trial Info
Start Date :
September 1 2009
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2012
Estimated Enrollment :
748 Patients enrolled
Trial Details
Trial ID
NCT02263833
Start Date
September 1 2009
End Date
August 1 2012
Last Update
September 7 2016
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Seoul, South Korea, 03080